415 related articles for article (PubMed ID: 20875764)
1. Use of cardiac magnetic resonance imaging to evaluate cardiac structure, function and fibrosis in children with infantile Pompe disease on enzyme replacement therapy.
Barker PC; Pasquali SK; Darty S; Ing RJ; Li JS; Kim RJ; DeArmey S; Kishnani PS; Campbell MJ
Mol Genet Metab; 2010 Dec; 101(4):332-7. PubMed ID: 20875764
[TBL] [Abstract][Full Text] [Related]
2. Effects of enzyme replacement therapy on cardiac function in classic infantile Pompe disease.
Scheffers LE; Kok R; van den Berg LE; van den Hout JMP; Boersma E; van Capelle CI; Helbing WA; van der Ploeg AT; Koopman LP
Int J Cardiol; 2023 Jun; 380():65-71. PubMed ID: 36893858
[TBL] [Abstract][Full Text] [Related]
3. Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase.
van Capelle CI; Poelman E; Frohn-Mulder IM; Koopman LP; van den Hout JMP; Régal L; Cools B; Helbing WA; van der Ploeg AT
Int J Cardiol; 2018 Oct; 269():104-110. PubMed ID: 30049495
[TBL] [Abstract][Full Text] [Related]
4. Pattern and prognostic value of cardiac involvement in patients with late-onset pompe disease: a comprehensive cardiovascular magnetic resonance approach.
Boentert M; Florian A; Dräger B; Young P; Yilmaz A
J Cardiovasc Magn Reson; 2016 Dec; 18(1):91. PubMed ID: 27931223
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.
Cook AL; Kishnani PS; Carboni MP; Kanter RJ; Chen YT; Ansong AK; Kravitz RM; Rice H; Li JS
Genet Med; 2006 May; 8(5):313-7. PubMed ID: 16702882
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up results in enzyme replacement therapy for Pompe disease: a case report.
Del Rizzo M; Fanin M; Cerutti A; Cazzorla C; Milanesi O; Nascimbeni AC; Angelini C; Giordano L; Bordugo A; Burlina AB
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S389-93. PubMed ID: 20830524
[TBL] [Abstract][Full Text] [Related]
7. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
[TBL] [Abstract][Full Text] [Related]
8. Electrocardiographic response to enzyme replacement therapy for Pompe disease.
Ansong AK; Li JS; Nozik-Grayck E; Ing R; Kravitz RM; Idriss SF; Kanter RJ; Rice H; Chen YT; Kishnani PS
Genet Med; 2006 May; 8(5):297-301. PubMed ID: 16702879
[TBL] [Abstract][Full Text] [Related]
9. Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the Multi-Ethnic Study of Atherosclerosis study.
Ambale Venkatesh B; Volpe GJ; Donekal S; Mewton N; Liu CY; Shea S; Liu K; Burke G; Wu C; Bluemke DA; Lima JA
Hypertension; 2014 Sep; 64(3):508-15. PubMed ID: 24914198
[TBL] [Abstract][Full Text] [Related]
10. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results.
Hamdan MA; Almalik MH; Mirghani HM
J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S431-6. PubMed ID: 19067231
[TBL] [Abstract][Full Text] [Related]
11. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
[TBL] [Abstract][Full Text] [Related]
12. Optimizing treatment outcomes: immune tolerance induction in Pompe disease patients undergoing enzyme replacement therapy.
Chen HA; Hsu RH; Fang CY; Desai AK; Lee NC; Hwu WL; Tsai FJ; Kishnani PS; Chien YH
Front Immunol; 2024; 15():1336599. PubMed ID: 38715621
[TBL] [Abstract][Full Text] [Related]
13. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alpha-glucosidase in infantile-onset Pompe disease.
Elder ME; Nayak S; Collins SW; Lawson LA; Kelley JS; Herzog RW; Modica RF; Lew J; Lawrence RM; Byrne BJ
J Pediatr; 2013 Sep; 163(3):847-54.e1. PubMed ID: 23601496
[TBL] [Abstract][Full Text] [Related]
14. Assessment of reverse remodeling predicted by myocardial deformation on tissue tracking in patients with severe aortic stenosis: a cardiovascular magnetic resonance imaging study.
Hwang JW; Kim SM; Park SJ; Cho EJ; Kim EK; Chang SA; Lee SC; Choe YH; Park SW
J Cardiovasc Magn Reson; 2017 Oct; 19(1):80. PubMed ID: 29061184
[TBL] [Abstract][Full Text] [Related]
15. [Enzyme replacement therapy in a boy with infantile Pompe disease: cardiac follow-up].
Bonnefoy R; Labarthe F; Paoli F; Chantreuil J; Barthez MA; Froissart R; Poinsot J; Chantepie A
Arch Pediatr; 2008 Dec; 15(12):1760-4. PubMed ID: 18995995
[TBL] [Abstract][Full Text] [Related]
16. Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease.
Levine JC; Kishnani PS; Chen YT; Herlong JR; Li JS
Pediatr Cardiol; 2008 Nov; 29(6):1033-42. PubMed ID: 18661169
[TBL] [Abstract][Full Text] [Related]
17. A beta-blocker, propranolol, decreases the efficacy from enzyme replacement therapy in Pompe disease.
Han SO; Pope R; Li S; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2016 Feb; 117(2):114-9. PubMed ID: 26454691
[TBL] [Abstract][Full Text] [Related]
18. Quantification of muscle pathology in infantile Pompe disease.
Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry Disease.
Hazari H; Belenkie I; Kryski A; White JA; Oudit GY; Thompson R; Fung T; Dehar N; Khan A
Can J Cardiol; 2018 Aug; 34(8):1041-1047. PubMed ID: 29935990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
